Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era.
Chakraborty R et al. Blood Cancer J. 2016 Dec 16;6(12):e512. doi: 10.1038/bcj.2016.117.
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival.
Botta C et al. Blood Cancer J. 2016 Dec 16;6(12):e511. doi: 10.1038/bcj.2016.118.
68Ga-PSMA PET/CT Imaging in Multiple Myeloma.
Sasikumar A et al. Clin Nucl Med. 2016 Dec 9. [Epub ahead of print].
Pretreatment neutrophil/lymphocyte ratio but not platelet/lymphocyte ratio has a prognostic impact in multiple myeloma.
Li Y et al. J Clin Lab Anal. 2016 Dec 7. doi: 10.1002/jcla.22107. [Epub ahead of print].
High serum levels of complements C3 and C4 as novel markers for myeloma bone disease.
Jiang F et al. Ann Hematol. 2016 Dec 7. [Epub ahead of print].
Improved Detection of Minimal Residual Disease by 11C-Methionine PET/CT in a Young Patient With Unusual Extramedullary Presentation of Recurrent Multiple Myeloma.
Caldarella C et al. Clin Nucl Med. 2016 Dec 3. [Epub ahead of print].
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents.
Tacchetti P et al. Haematologica. 2016 Dec 1. pii: haematol.2016.154070. [Epub ahead of print].
Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting.
de Waal EG et al. Eur J Nucl Med Mol Imaging. 2016 Nov 29. [Epub ahead of print].
Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma.
Mithraprabhu S et al. Leukemia. 2016 Nov 30. doi: 10.1038/leu.2016.366. [Epub ahead of print].
A panel of circulating miRNAs as diagnostic biomarkers for screening multiple myeloma: a systematic review and meta-analysis.
Zhang L et al. Int J Lab Hematol. 2016 Dec;38(6):589-599. doi: 10.1111/ijlh.12560.